1. Home
  2. QQQX vs SPRY Comparison

QQQX vs SPRY Comparison

Compare QQQX & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest

QQQX

Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest

HOLD

Current Price

$28.04

Market Cap

1.3B

Sector

Finance

ML Signal

HOLD

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$10.36

Market Cap

946.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QQQX
SPRY
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
946.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
QQQX
SPRY
Price
$28.04
$10.36
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$31.25
AVG Volume (30 Days)
127.6K
2.1M
Earning Date
01-01-0001
11-10-2025
Dividend Yield
7.03%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$142,772,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$124.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5459.66
52 Week Low
$20.27
$6.66
52 Week High
$25.99
$18.90

Technical Indicators

Market Signals
Indicator
QQQX
SPRY
Relative Strength Index (RSI) 50.49 58.86
Support Level $28.18 $9.77
Resistance Level $28.62 $11.45
Average True Range (ATR) 0.34 0.66
MACD 0.04 0.25
Stochastic Oscillator 64.80 72.24

Price Performance

Historical Comparison
QQQX
SPRY

About QQQX Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest

Nuveen NASDAQ 100 Dynamic Overwrite Fund is a closed-end management investment company. Its investment objective is to seek an attractive total return with less volatility than the Nasdaq 100 Index. Under normal circumstances, the Fund will invest at least 80% of its Assets in an equity portfolio made up of securities comprising the Nasdaq 100 Index (or securities that have economic characteristics that are similar to those securities comprising the Nasdaq 100 Index) that seeks to substantially replicate price movements of the Nasdaq 100 Index and is designed to support the Fund's option strategy.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Share on Social Networks: